Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ847,5849,5-0,53
KB8408410,90
PKN65,1865,22,29
Msft421,12421,38-0,02
Nokia3,2933,2965-1,41
IBM190,65191,540,26
Mercedes-Benz Group AG73,9573,960,60
PFE27,7827,790,04
28.03.2024 13:59:55
Indexy online
AD Index online
select
AD Index online
 

  • 21.03.2024 17:38:17
ACADIA Pharm (DR6.F, Frankfurt)
Poslední obchod Změna (%) Změna (EUR) Objem obchodů (EUR)
17,00 1,84 0,30 4 420
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 28.03.2024
Popis společnosti
Obecné informace
Název společnostiACADIA Pharmaceuticals Inc
TickerACAD
Kmenové akcie:Ordinary Shares
RICACAD.O
ISINUS0042251084
Prioritní akcieConv. Pref. Shrs
Poslední známé roční výsledky31.12.2023
Poslední známé čtvrtletní výsledky31.12.2023
Počet zaměstnanců k 31.12.2023 597
Akcie v oběhu k 21.02.2024 164 771 521
MěnaUSD
Kontaktní informace
Ulice12830 El Camino Real, Suite 400
MěstoSAN DIEGO
PSČ92130
ZeměUnited States
Kontatní osobaMark Johnson
Funkce kontaktní osobyVice President, Investor Relations
Telefon18 585 582 871
Fax18585582872
Kontatní telefon18 585 582 871

Business Summary: Acadia Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has a portfolio of commercial stage products, in-development product opportunities, and research programs that are designed to address unmet needs in CNS disorders and rare diseases. Its pipeline includes NUPLAZID (pimavanserin), DAYBUE (trofinetide), ACP-101, ACP-204, and Antisense Oligonucleotide (ASO) Programs. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. Trofinetide is a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 (IGF-1) designed to treat the core symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, ACADIA Pharmaceuticals Inc revenues increased 40% to $726.4M. Net loss decreased 72% to $61.3M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Interest Income, net increase from $6.6M to $17.2M (income), Stock-Based Compensation in R&D decrease of 23% to $17.4M (expense).
Odvětvová klasifikace
TRBC2009Biotechnology / Medical Research
TRBC2012Biotechnology & Medical Research (NEC)
RBSS2004Biotechnology
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSPharmaceutical Preparation Manufacturing
NAICSResearch and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
NAICS2007Pharmaceutical Preparation Mfg
NAICS2007Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
NAICS1997Pharmaceutical Preparation Manufacturing
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
SICPharmaceutical Preparations
SICPharmaceutical Preparations
SICCommercial Physical Research



  • Poslední aktualizace: 28.03.2024
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chief Executive Officer, DirectorStephen Davis6230.03.201915.07.2014
Chief Financial Officer, Executive Vice PresidentMark Schneyer4909.12.202109.12.2021
Chief Operating Officer, Executive Vice President, Head of CommercialBrendan Teehan5401.11.202101.11.2021
Executive Vice President - Research and DevelopmentDouglas Williamson6009.01.202309.01.2023
Senior Vice President, Investor Relations and Corporate CommunicationsAlbert Kildani-19.09.202319.09.2023
Senior Vice President, Chief Business OfficerKevin Oliver5310.07.202310.07.2023